Russell P. Gollard, MD, FACP, explores effective collaboration among health care professionals, administrators, and specialty pharmacies in managing rare diseases like hemophilia A.
Russell P. Gollard, MD, FACP, discusses how the rising costs of managing hemophilia A are influenced by drug expenses, treatment efficacy, and adverse events, creating significant financial burdens across health care settings and patient populations.
A simulation study estimated the impact of biosimilar substitution on total cost of care (TCOC) and provider financial performance in the final performance period of the Oncology Care Model.
Russell P. Gollard, MD, FACP, discusses coverage decisions for expensive treatments in hemophilia, including total cost of care, drug availability, and real-world evidence.